JP2016509019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509019A5 JP2016509019A5 JP2015557533A JP2015557533A JP2016509019A5 JP 2016509019 A5 JP2016509019 A5 JP 2016509019A5 JP 2015557533 A JP2015557533 A JP 2015557533A JP 2015557533 A JP2015557533 A JP 2015557533A JP 2016509019 A5 JP2016509019 A5 JP 2016509019A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- population
- composition
- human mammal
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002919 epithelial cell Anatomy 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 210000000069 breast epithelial cell Anatomy 0.000 claims 2
- 230000033581 fucosylation Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 1
- 241000157302 Bison bison athabascae Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282842 Lama glama Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764488P | 2013-02-13 | 2013-02-13 | |
| US61/764,488 | 2013-02-13 | ||
| PCT/IB2014/000711 WO2014125377A2 (en) | 2013-02-13 | 2014-02-13 | Highly galactosylated anti-her2 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238917A Division JP2020125286A (ja) | 2013-02-13 | 2019-12-27 | 高ガラクトシル化抗ｈｅｒ２抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016509019A JP2016509019A (ja) | 2016-03-24 |
| JP2016509019A5 true JP2016509019A5 (enExample) | 2017-03-09 |
Family
ID=50980322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557533A Pending JP2016509019A (ja) | 2013-02-13 | 2014-02-13 | 高ガラクトシル化抗ｈｅｒ２抗体およびその使用 |
| JP2019238917A Pending JP2020125286A (ja) | 2013-02-13 | 2019-12-27 | 高ガラクトシル化抗ｈｅｒ２抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238917A Pending JP2020125286A (ja) | 2013-02-13 | 2019-12-27 | 高ガラクトシル化抗ｈｅｒ２抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150368357A1 (enExample) |
| EP (1) | EP2956485A2 (enExample) |
| JP (2) | JP2016509019A (enExample) |
| KR (1) | KR20160003634A (enExample) |
| CN (1) | CN105308071A (enExample) |
| AR (1) | AR094781A1 (enExample) |
| AU (1) | AU2014217564B2 (enExample) |
| BR (1) | BR112015019343A2 (enExample) |
| CA (1) | CA2900912A1 (enExample) |
| IL (1) | IL240440A0 (enExample) |
| MX (1) | MX2015010428A (enExample) |
| TW (1) | TW201444870A (enExample) |
| WO (1) | WO2014125377A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG191781A1 (en) | 2010-12-30 | 2013-08-30 | Lab Francais Du Fractionnement | Glycols as pathogen inactivating agents |
| BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
| AU2014217561B2 (en) | 2013-02-13 | 2018-11-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-alpha antibodies and uses thereof |
| US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
| EP3191527B1 (en) * | 2014-09-10 | 2020-01-15 | F.Hoffmann-La Roche Ag | Galactoengineered immunoglobulin 1 antibodies |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药（苏州）股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
| FR3060395B1 (fr) * | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
| AU2019282264A1 (en) * | 2018-06-05 | 2020-11-26 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
| US12103978B2 (en) | 2018-06-15 | 2024-10-01 | Shanghai Miracogen Inc. | Methods and materials for treating cancer |
| EP4190818A4 (en) * | 2020-07-28 | 2024-08-07 | Bio-Thera Solutions, Ltd. | ANTI-HER2 ANTIBODY AND ITS USE |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| AU3657899A (en) * | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| EP2042196B1 (en) * | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| US20040101939A1 (en) * | 2002-11-22 | 2004-05-27 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| ES2417147T3 (es) | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| EP2035034A4 (en) * | 2006-06-09 | 2009-11-18 | Univ Maryland | GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY |
| JP5638804B2 (ja) * | 2006-08-04 | 2014-12-10 | アストラゼネカ アクチボラグ | ＥｒｂＢ２に対する抗体 |
| PT2073842E (pt) * | 2006-09-10 | 2015-04-07 | Glycotope Gmbh | Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos |
| CN101588817B (zh) * | 2006-09-10 | 2013-06-12 | 葛莱高托普有限公司 | 骨髓白血病来源的细胞在抗体表达中的用途 |
| EP2244735A4 (en) * | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE |
| CN102216452B (zh) * | 2008-09-26 | 2013-08-21 | 尤里卡治疗公司 | 具有变异糖基化方式的细胞系和蛋白质 |
| WO2012105699A1 (ja) * | 2011-02-03 | 2012-08-09 | 株式会社イーベック | 補体依存性生物活性の高い抗体の産生法 |
| US8809017B2 (en) * | 2011-05-24 | 2014-08-19 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
| AU2014217561B2 (en) * | 2013-02-13 | 2018-11-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-alpha antibodies and uses thereof |
-
2014
- 2014-02-13 CN CN201480020373.3A patent/CN105308071A/zh active Pending
- 2014-02-13 MX MX2015010428A patent/MX2015010428A/es unknown
- 2014-02-13 US US14/767,120 patent/US20150368357A1/en not_active Abandoned
- 2014-02-13 KR KR1020157024975A patent/KR20160003634A/ko not_active Withdrawn
- 2014-02-13 WO PCT/IB2014/000711 patent/WO2014125377A2/en not_active Ceased
- 2014-02-13 CA CA2900912A patent/CA2900912A1/en not_active Abandoned
- 2014-02-13 AR ARP140100460A patent/AR094781A1/es unknown
- 2014-02-13 JP JP2015557533A patent/JP2016509019A/ja active Pending
- 2014-02-13 BR BR112015019343A patent/BR112015019343A2/pt not_active Application Discontinuation
- 2014-02-13 TW TW103104772A patent/TW201444870A/zh unknown
- 2014-02-13 AU AU2014217564A patent/AU2014217564B2/en not_active Ceased
- 2014-02-13 EP EP14732000.6A patent/EP2956485A2/en not_active Withdrawn
-
2015
- 2015-08-09 IL IL240440A patent/IL240440A0/en unknown
-
2019
- 2019-12-27 JP JP2019238917A patent/JP2020125286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508515A5 (enExample) | ||
| JP2014525395A5 (enExample) | ||
| JP2016513105A5 (enExample) | ||
| BR112015019341A2 (pt) | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal | |
| ZA201703241B (en) | Anti-c5 antibodies and methods of use | |
| SG194466A1 (en) | Non-human animals expressing antibodies having a common light chain | |
| MX2022008124A (es) | Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano. | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| WO2015112790A8 (en) | High-throughput mouse model for optimizing antibody affinities | |
| WO2015127136A3 (en) | Ebola monoclonal antibodies | |
| WO2011131746A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| MX395317B (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| HK1253693A1 (zh) | 产生抗t细胞受体的抗体的方法 | |
| PH12019502730A1 (en) | Method of manufacturing bispecific antibodies and therapeutic use of such antibodies | |
| WO2015173756A3 (en) | Bispecific antibodies with engineered ch1-cl interfaces | |
| SA518391704B1 (ar) | C5 أجسام مضادة لـ وطرق لاستخدامها | |
| IN2014DN08163A (enExample) | ||
| AR096839A1 (es) | Proceso mejorado para la producción de anticuerpos monoclonales | |
| MX2017012399A (es) | Anticuerpos monoclonales anti-cd303. | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
| IL276211A (en) | HU14.18K322A monoclonal antibody production process | |
| BR112015019343A2 (pt) | Anticorpo anti-her2, composição, método para produção de uma população de anticorpos, células epiteliais das glândulas mamárias, e, mamífero não humano transgênico | |
| JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
| BR112016021679A2 (pt) | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. |